share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/10/30 04:19

Moomoo AI 已提取核心訊息

BioVie announced the closing of its registered direct offering on October 28, 2024, successfully raising $3.24 million through the sale of 1,146,000 shares of common stock at $2.83 per share. The net proceeds, after deducting approximately $419,254 in placement agent fees and offering expenses, will be primarily used for working capital and general corporate purposes.The offering was conducted under the company's shelf registration statement, with ThinkEquity serving as the sole placement agent. BioVie, a clinical-stage company, focuses on developing innovative drug therapies for neurological disorders including Long COVID, Alzheimer's disease, Parkinson's disease, and advanced liver disease.The company's key drug candidates include bezisterim for neurodegenerative diseases and BIV201, an FDA Fast Track-designated Orphan drug candidate for liver cirrhosis complications. BIV201 is currently under discussion with the FDA regarding Phase 3 clinical testing design.
BioVie announced the closing of its registered direct offering on October 28, 2024, successfully raising $3.24 million through the sale of 1,146,000 shares of common stock at $2.83 per share. The net proceeds, after deducting approximately $419,254 in placement agent fees and offering expenses, will be primarily used for working capital and general corporate purposes.The offering was conducted under the company's shelf registration statement, with ThinkEquity serving as the sole placement agent. BioVie, a clinical-stage company, focuses on developing innovative drug therapies for neurological disorders including Long COVID, Alzheimer's disease, Parkinson's disease, and advanced liver disease.The company's key drug candidates include bezisterim for neurodegenerative diseases and BIV201, an FDA Fast Track-designated Orphan drug candidate for liver cirrhosis complications. BIV201 is currently under discussion with the FDA regarding Phase 3 clinical testing design.
BioVie於2024年10月28日宣佈其註冊直接發行的結束，成功籌集了324萬美元，通過以每股2.83美元的價格出售1,146,000股普通股。扣除約419,254美元的承銷代理費用和發行費用後，淨收益將主要用於營運資金和一般公司用途。此次發行是在公司貨架註冊聲明下進行的，ThinkEquity擔任唯一承銷代理。BioVie是一家臨牀階段公司，專注於開發創新藥物療法，治療包括長新冠、阿爾茲海默病、帕金森病和晚期肝病在內的神經系統疾病。公司的主要候選藥物包括用於神經退行性疾病的bezisterim和BIV201，後者是一種被FDA快速通道指定的孤兒藥候選藥物，旨在治療肝硬化併發症。目前，BIV201正與FDA討論第三階段臨牀測試設計。
BioVie於2024年10月28日宣佈其註冊直接發行的結束，成功籌集了324萬美元，通過以每股2.83美元的價格出售1,146,000股普通股。扣除約419,254美元的承銷代理費用和發行費用後，淨收益將主要用於營運資金和一般公司用途。此次發行是在公司貨架註冊聲明下進行的，ThinkEquity擔任唯一承銷代理。BioVie是一家臨牀階段公司，專注於開發創新藥物療法，治療包括長新冠、阿爾茲海默病、帕金森病和晚期肝病在內的神經系統疾病。公司的主要候選藥物包括用於神經退行性疾病的bezisterim和BIV201，後者是一種被FDA快速通道指定的孤兒藥候選藥物，旨在治療肝硬化併發症。目前，BIV201正與FDA討論第三階段臨牀測試設計。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    ImmunoPrecise Antibodies
    IPA
    -- 0.655
    Absci Corp
    ABSI
    -- 4.205
    Nutriband
    NTRB
    -- 6.720
    Seres Therapeutics
    MCRB
    -- 0.928
    Rein Therapeutics
    RNTX
    -- 2.438
    解鎖完整榜單
    熱門中概股
    追蹤最熱門的中概股實時資訊。
    熱門討論
    特朗普回歸，業績發佈在即：特斯拉能否繼續攀升？
    🎙️討論： 1. 面對特朗普回歸，特斯拉股價能否在2025年繼續攀升？ 2. 特斯拉將於1月29日收盤後公布財報，你認為會超出市場預期嗎？ 展开
    🚗 特斯拉第四季度下跌：是時候買入了，還是風險太高？📉